Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

495 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005.
Jackson K, Gersh BJ, Stockbridge N, Fleming TR, Temple R, Califf RM, Connolly SJ, Wallentin L, Granger CB; Duke Clinical Research Institute/American Heart Journal Expert Meeting on Antithrombotic Drug Development for Atrial Fibrillation. Jackson K, et al. Among authors: connolly sj. Am Heart J. 2008 May;155(5):829-40. doi: 10.1016/j.ahj.2008.01.023. Am Heart J. 2008. PMID: 18440329 Review.
Left Atrial Appendage Occlusion Study (LAAOS): a randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention.
Crystal E, Lamy A, Connolly SJ, Kleine P, Hohnloser SH, Semelhago L, Abouzhar L, Cybulsky I, Shragge B, Teoh K, Lonn E, Sawchuk C, Oezaslan F; Left Atrial Appendage Occlusion Study. Crystal E, et al. Among authors: connolly sj. Am Heart J. 2003 Jan;145(1):174-8. doi: 10.1067/mhj.2003.44. Am Heart J. 2003. PMID: 12514671 Clinical Trial.
Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study.
Flaker G, Ezekowitz M, Yusuf S, Wallentin L, Noack H, Brueckmann M, Reilly P, Hohnloser SH, Connolly S. Flaker G, et al. J Am Coll Cardiol. 2012 Feb 28;59(9):854-5. doi: 10.1016/j.jacc.2011.10.896. J Am Coll Cardiol. 2012. PMID: 22361407 Free article. No abstract available.
Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study.
Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, Eikelboom J, Themeles E, Ezekowitz M, Wallentin L, Yusuf S; RE-LY Investigators. Marijon E, et al. Circulation. 2013 Nov 12;128(20):2192-201. doi: 10.1161/CIRCULATIONAHA.112.000491. Epub 2013 Sep 9. Circulation. 2013. PMID: 24016454 Clinical Trial.
Response to letter regarding article, "Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study".
Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, Eikelboom J, Themeles E, Ezekowitz M, Wallentin L, Yusuf S. Marijon E, et al. Circulation. 2014 Aug 26;130(9):e85. doi: 10.1161/CIRCULATIONAHA.114.010275. Circulation. 2014. PMID: 25156923 No abstract available.
495 results